Curcumin as an anti-proliferative agent in breast cancer through RASSF1A, Bax, and caspase-3 protein

Background. Curcumin is a polyphenol that has pharmacological activity that can inhibit tumor cell growth and induce apoptosis through various mechanisms. However, the specifc mechanism of curcumin cytotoxicity remains controversial because of many anti- and pro-apoptotic signaling pathways in vario...

Full description

Bibliographic Details
Main Authors: N. A. Rahmah, H. Harliansyah, F. D. Suyatna, M. Kanoko, P. Rustamadji, J. Prihartono, A. Bustami, S. J. Haryono, B. S. Hernowo
Format: Article
Language:Russian
Published: Russian Academy of Sciences, Tomsk National Research Medical Center 2023-01-01
Series:Сибирский онкологический журнал
Subjects:
Online Access:https://www.siboncoj.ru/jour/article/view/2378
Description
Summary:Background. Curcumin is a polyphenol that has pharmacological activity that can inhibit tumor cell growth and induce apoptosis through various mechanisms. However, the specifc mechanism of curcumin cytotoxicity remains controversial because of many anti- and pro-apoptotic signaling pathways in various cell types.This study aims to examine the relationship among curcumin on RASSF1A, Bax protein levels, and caspase-3 activity in supporting the apoptotic mechanism in CSA03 breast cancer cells.Material and Methods. Curcumin administration to cancer cells is based on differences in dosage with 24-hour incubation. Cytotoxicity after curcumin administration was determined using MTS. RASSF1A and Bax protein levels were tested through ELISA. Caspase-3 activity was used to determine apoptosis and was tested using fow cytometry.Results. The results indicated that curcumin had a cytotoxicity effect of 40.85 µg/mL. At concentrations of 40 µg/mL and 50 µg/mL, curcumin increases levels of protein RASSF1A (∆ = 26.53% and 47.35%, respectively), Bax (∆ = 48.79% and 386.15%), and caspase-3 (∆ = 1,678.51% and 1,871.889%) signifcantly.Conclusions. Curcumin exhibits anti-proliferative activity and apoptotic (Caspase-3) effects through activation of RASSF1A and Bax.
ISSN:1814-4861
2312-3168